Mark Blitzer, MD
Cardiovascular Disease · New Haven, CTNPI 1164428207
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (58.4%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 4 manufacturers reported payments, led by Boston Scientific at 59.4% of the total. Reporting peaked in 2024 at $3,647 and has fallen 95.7% since, to $156 in 2025.
Across 32 payments — averaging $183.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$3K
- Medtronic$2K
- Biosense Webster, Inc.$229
- Abbott$103
What the payments were for
- Consulting fees$3,43858%
- Travel & lodging$72312%
- Food & beverage$1,65428%
- Education$701%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 4 | $3,498 |
| Medtronic(2 entities) | 24 | $2,055 |
| Biosense Webster, Inc. | 3 | $229 |
| Abbott | 1 | $103 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GENERAL - THERAPIES$156
- Micra$152
- Carto 3$147
- AVEIR$103
How this compares
$5,885 in reported general payments places this provider in the 75th percentile of 415 cardiovascular disease providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 342 | $463,081 |
| XareltoRivaroxaban | 122 | $170,547 |
| Flecainide Acetate | 191 | $10,682 |
| Dofetilide | 23 | $10,311 |
| Amiodarone Hcl | 151 | $6,058 |
| Metoprolol Succinate | 429 | $5,664 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 94 | $4,614 |
| Mexiletine Hcl | 32 | $3,740 |
| SotalolSotalol Hcl | 91 | $2,120 |
| Midodrine Hcl | 16 | $680 |
| Rosuvastatin Calcium | 43 | $515 |
| Carvedilol | 52 | $457 |
| Lisinopril | 39 | $282 |
| Metoprolol Tartrate | 59 | $251 |
| Levothyroxine Sodium | 14 | $249 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in New Haven
- Nihar DesaiNew Haven$1.4M
- Jeffery TestaniNew Haven$546K
- Carlos Mena-HurtadoNew Haven$460K
- John ForrestNew Haven$164K
- Henry WardNew Haven$152K
- Cesia Maria Gallegos KattanNew Haven$101K
- Khurram NasirNew Haven$100K
- Tariq AhmadNew Haven$75K
- Joseph AkarNew Haven$74K
- Hyung ChunNew Haven$67K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.